Waldenstrom’s macroglobulinaemia is a rare, slow-growing blood cancer that requires a careful, personalized approach to treatment, balancing the need to control symptoms with maintaining quality of life over what can be many years of living with this condition.

Understanding Treatment Goals and Approaches

When someone receives a diagnosis of Waldenstrom’s macroglobulinaemia, often shortened to WM, the first thing to understand is that treatment decisions are never rushed. This condition typically grows slowly, and the approach to care depends heavily on whether symptoms are present, how advanced the disease is, and the overall health of the person affected. The main goals of treatment are to reduce symptoms caused by the disease, prevent complications, improve quality of life, and extend the time during which the condition remains under control.^[1][2]

Not everyone diagnosed with WM needs treatment right away. In fact, about one in four people with this condition have no symptoms at all when they are first diagnosed.^[2] For these individuals, doctors often recommend an approach called active surveillance, sometimes called watchful waiting or active monitoring. This means the medical team closely monitors the disease through regular check-ups, blood tests, and physical examinations, but does not start active treatment until it becomes necessary.^[9][10]

Treatment becomes necessary when the disease starts causing problems. These problems might include severe fatigue, a significant drop in healthy blood cells, enlarged organs like the spleen or liver, nerve damage causing tingling or numbness, or a thickening of the blood that can lead to serious complications like bleeding, vision problems, or confusion.^[1][2] The decision to start treatment is always made together with the healthcare team, taking into account the specific symptoms, the rate at which the disease is progressing, and what matters most to the person living with WM.

Modern medicine offers several treatment options for WM, ranging from well-established therapies that have been used for years to newer drugs that are being tested in clinical trials — carefully designed research studies that evaluate how well new treatments work. There is no single “best” treatment for everyone with WM. Instead, doctors choose therapies based on each person’s unique situation, including their age, overall fitness, previous treatments if any, and how long any previous treatment kept the disease under control.^[9][10]

Standard Treatment Options for Waldenstrom’s Macroglobulinaemia

The foundation of WM treatment for many years has been combinations of different drugs, often including a type of medicine called rituximab along with various chemotherapy drugs (medicines that kill cancer cells) or other targeted agents. Rituximab is a monoclonal antibody, which means it is a laboratory-made protein that attaches to specific markers on the surface of the abnormal cells in WM, helping the immune system recognize and destroy them.^[9][10]

One of the most commonly used treatment combinations is bendamustine with rituximab, often shortened to BR. Bendamustine is a chemotherapy drug that damages the genetic material inside cancer cells, preventing them from growing and dividing. When given together with rituximab, this combination has shown strong results in controlling WM.^[9][14] Studies comparing different treatment approaches have found that BR produces high response rates, meaning the treatment successfully reduces the amount of disease in many people who receive it. In research studies, about 46 out of every 100 people treated with BR had their disease significantly reduced.^[14]

Another effective combination includes bortezomib, dexamethasone, cyclophosphamide, and rituximab, abbreviated as BDRC or sometimes BDR. Bortezomib is a proteasome inhibitor, which works by blocking a system inside cells that breaks down old proteins. When this system is blocked, abnormal proteins build up inside the cancer cells, eventually causing them to die. Dexamethasone is a strong anti-inflammatory steroid that also helps kill lymphoma cells. Cyclophosphamide is another chemotherapy drug.^[9] This combination is particularly useful in certain situations, though it may cause side effects like numbness or tingling in the hands and feet, a condition called peripheral neuropathy, which happens more frequently with bortezomib.^[14]

A significant development in WM treatment came in 2015 when ibrutinib became the first drug specifically approved by the United States Food and Drug Administration for treating people newly diagnosed with this condition.^[9] Ibrutinib belongs to a class of drugs called Bruton Tyrosine Kinase inhibitors, or BTK inhibitors. These medicines work by blocking a specific protein called BTK that sends signals telling the cancer cells to survive and multiply. When BTK is blocked, the cancer cells can no longer receive these survival signals and they die.^[9][10]

Ibrutinib is taken as a pill every day, which many people find more convenient than intravenous treatments that require visits to a hospital or clinic.^[20] It has proven effective at reducing the amount of abnormal protein in the blood and shrinking enlarged lymph nodes or organs. One person’s experience showed that their abnormal protein levels dropped by 85 percent in just twelve weeks after starting ibrutinib.^[20] However, ibrutinib needs to be taken continuously as long as it continues to work and side effects remain manageable, unlike chemotherapy combinations that are given for a set period and then stopped.

The duration of treatment varies depending on which approach is used. Chemotherapy-based combinations are typically given for a fixed period, often ranging from several months to about 18 months, with regular cycles of treatment followed by rest periods to allow the body to recover.^[20] During this time, patients receive their medications through intravenous infusions at treatment centers. In contrast, BTK inhibitors like ibrutinib are taken daily at home and continued indefinitely, as long as they remain effective and tolerable.

All treatments for WM can cause side effects, though their nature and severity differ between approaches. Chemotherapy-based treatments more commonly cause temporary decreases in blood cell counts, which can lead to increased risk of infection, anemia causing fatigue, and easier bruising or bleeding.^[2] Nausea, hair loss, and fatigue are also possible with chemotherapy. Bortezomib has a particular tendency to cause peripheral neuropathy, with tingling, numbness, or pain in the hands and feet.^[14]

BTK inhibitors like ibrutinib have a different side effect profile. They can affect the heart’s rhythm in some people, a concern that requires monitoring especially in those with existing heart conditions.^[14] They may also increase the risk of bleeding because they affect platelet function. Other possible side effects include joint pain, muscle aches, diarrhea, and fatigue. Each person’s experience with side effects is different, and the medical team works to manage these effects while maintaining the benefits of treatment.

Innovative Treatments Being Studied in Clinical Trials

Beyond the standard treatments already available, researchers around the world are testing new and promising approaches to treating WM through clinical trials. These studies are essential for advancing our understanding of the disease and developing better treatment options for the future. Clinical trials proceed through different phases, each designed to answer specific questions about a new treatment.

Phase I trials are the first step, where researchers carefully study a new treatment in a small number of people to understand its safety, determine the right dose, and identify side effects. Phase II trials include more people and focus on whether the treatment actually works against the disease while continuing to monitor safety. Phase III trials involve even larger groups of patients and compare the new treatment directly against current standard treatments to see which works better or has fewer side effects.

Several newer BTK inhibitors are being evaluated in clinical trials for WM. Acalabrutinib and zanubrutinib are similar to ibrutinib but were designed to be more specific in their action, potentially causing fewer side effects, particularly heart-related ones.^[9][16] Zanubrutinib, for instance, has been approved in some countries and is being tested specifically in WM patients. Another BTK inhibitor called tirabrutinib is also under investigation.^[9] Early results from trials of these newer BTK inhibitors suggest they can effectively reduce disease while potentially being easier to tolerate than the first-generation drug.

Daratumumab represents another innovative approach being tested in WM. This is a monoclonal antibody that targets a different protein on the surface of the abnormal cells, called CD38.^[9] Daratumumab has proven effective in treating multiple myeloma, another blood cancer, and researchers are investigating whether it can help people with WM, especially when combined with other treatments.

Ulocuplumab is yet another monoclonal antibody being studied in clinical trials for WM.^[9] It works by targeting a protein called CXCR4, which is involved in helping cancer cells survive and migrate to different parts of the body. Researchers have discovered that about 40 percent of people with WM have mutations in the CXCR4 gene,^[2] and treatments targeting this protein might be particularly helpful for this subset of patients.

A fascinating area of research involves CAR T-cell therapy, a form of immunotherapy where a person’s own immune cells are collected, genetically modified in a laboratory to recognize and attack the cancer cells, and then infused back into the patient. One such therapy being studied is called 19(T2)28z1XX, which targets a protein called CD19 found on WM cells.^[9] This represents a potentially powerful way to harness the body’s own immune system to fight the disease. CAR T-cell therapy has shown remarkable results in other types of lymphoma and is now being explored for WM.

Clinical trials for WM are conducted in many locations around the world, including the United States, Europe, and other regions. Eligibility for these trials depends on many factors, including the stage of disease, previous treatments received, overall health status, and specific characteristics of the cancer cells. People interested in clinical trials can discuss options with their medical team or search clinical trial databases to find studies that might be appropriate for their situation.^[9]

For people whose WM returns after initial treatment, called relapsed disease, or for those whose disease does not respond well to treatment, called refractory disease, several options exist. The choice depends on what treatment was used before and how long it worked. If the previous treatment controlled the disease for a long time, sometimes that same treatment can be tried again. If the disease came back quickly, usually within 12 months, switching to a different type of treatment is recommended.^[15]

For people who received chemotherapy-based treatment initially and then relapsed, ibrutinib is often an excellent option because it works through a completely different mechanism.^[15] Conversely, for those who were on ibrutinib and experienced disease progression, switching to chemotherapy combinations or trying one of the newer BTK inhibitors might be appropriate. Some studies are exploring whether combining different types of drugs — for instance, a BTK inhibitor with rituximab — might work better than single agents.^[9]

Researchers continue to study combinations of drugs that have not traditionally been used together in WM. For example, some trials are testing whether adding drugs like lenalidomide, carfilzomib, or ixazomib to standard treatments improves outcomes.^[9][16] The goal of all this research is to find treatments that work more effectively, cause fewer side effects, can be given for shorter durations, or help people live longer, healthier lives.

Most Common Treatment Methods

• Chemotherapy-based combinations
  • Bendamustine with rituximab (BR) — a frequently used combination that damages cancer cell DNA while the antibody helps the immune system target abnormal cells
  • Cyclophosphamide, vincristine, and prednisone (CVP) — an older combination still used in some situations
  • CHOP regimen — cyclophosphamide, doxorubicin, vincristine, and prednisone, sometimes with rituximab added
  • Fludarabine or cladribine-based treatments — chemotherapy drugs that are particularly effective against lymphoma cells
  • Chlorambucil — an older chemotherapy drug sometimes used in less aggressive disease
• Targeted therapy with proteasome inhibitors
  • Bortezomib combined with rituximab and other drugs — blocks the protein-breakdown system in cancer cells
  • Carfilzomib — another proteasome inhibitor being studied in WM
  • Ixazomib — an oral proteasome inhibitor under investigation
• BTK inhibitors
  • Ibrutinib — the first BTK inhibitor approved for WM, taken as a daily pill
  • Acalabrutinib — a more selective BTK inhibitor being tested in trials
  • Zanubrutinib — another newer BTK inhibitor with potentially fewer side effects
  • Tirabrutinib — an investigational BTK inhibitor
• Monoclonal antibody therapy
  • Rituximab — targets CD20 protein on lymphoma cells, often used in combination with other drugs
  • Daratumumab — targets CD38 protein, being studied in clinical trials for WM
  • Ulocuplumab — targets CXCR4 protein, under investigation in research studies
• Plasmapheresis
  • Emergency procedure to rapidly remove excess abnormal proteins from blood when it becomes dangerously thick
  • Provides temporary relief while other treatments take effect
• Immunotherapy approaches
  • CAR T-cell therapy such as 19(T2)28z1XX — genetically modified immune cells that target cancer cells, being tested in clinical trials
• Immunomodulatory drugs
  • Lenalidomide — affects the immune system and bone marrow environment, sometimes used in combination treatments
  • Thalidomide — an older drug with immunomodulatory effects, occasionally used with rituximab

Living Well During and After Treatment

Treatment for WM is only one part of managing this condition. Many other factors contribute to overall health and wellbeing during the journey with this disease. Staying as healthy as possible through lifestyle choices can help people feel better, cope more effectively with treatment side effects, and potentially improve outcomes.

Maintaining a nutritious, balanced diet is important. While there is no special diet that cures or treats WM, eating a variety of fruits, vegetables, whole grains, and adequate protein helps support the body during treatment and recovery.^[18][23] Some people may need to follow specific dietary precautions during chemotherapy, particularly when white blood cell counts are low, to reduce infection risk. This might mean avoiding raw or undercooked foods temporarily. Working with a registered dietitian can provide personalized guidance.

Some vitamin deficiencies are common in WM for reasons that are not completely understood. Vitamin B12, folate, and vitamin D levels should be checked regularly, and deficiencies can be easily corrected with supplements or injections.^[23] Iron deficiency can also occur and contribute to anemia. Vitamin D supplementation at a dose of about 1000 IU daily is often recommended because this vitamin plays important roles in bone health and immune function.

Physical activity can help combat the fatigue that is one of the most common and challenging symptoms of WM and its treatment. While severe tiredness may make exercise seem impossible, even gentle movement like short walks, stretching, or chair exercises can help improve energy levels over time.^[18][19] It is important to listen to the body and rest when needed, but complete inactivity can actually worsen fatigue. Finding a balance and gradually building activity as tolerated is the goal.

Preventing infections is crucial, especially during treatment when the immune system may be weakened. Simple measures like frequent handwashing, avoiding crowds when blood counts are low, staying up to date with recommended vaccinations (including annual flu shots and pneumonia vaccines), and promptly reporting any signs of infection to the medical team can help prevent serious complications.^[19][23] During the COVID-19 pandemic, people with WM have needed to be particularly vigilant about protective measures like mask-wearing and avoiding crowded indoor spaces.

The emotional impact of living with a cancer diagnosis cannot be underestimated. Many people experience anxiety, fear, sadness, or anger at various points in their journey with WM. These feelings are completely normal and expected.^[23] Connecting with others who have WM through support groups, either in person or online, can provide tremendous comfort and practical advice. Professional counseling or therapy can also be invaluable in developing coping strategies. Many cancer centers offer supportive services including social workers, psychologists, and support groups specifically for people with blood cancers.

Keeping organized medical records is practical and empowering. This might include a list of all medications, treatment dates and types, test results, doctor contact information, and questions to ask at appointments. Having this information readily available makes medical visits more productive and ensures continuity of care if seeing different specialists or getting second opinions.

Many people with WM are able to continue working during treatment, especially with oral medications like BTK inhibitors. However, fatigue, treatment schedules, and side effects may require adjustments to work responsibilities or schedules. Open communication with employers and taking advantage of available accommodations can help maintain work-life balance when desired.